pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2013-0-6-85-91pulmo-313Research ArticleОБЗОРЫREVIEWМедикаментозные средства предотвращения и минимизации лучевых повреждений легкихDrug therapy to prevent and diminish radiation injury of the lungsСычеваМ. Г.SychevaM. G.

к. м. н., ст. научный сотрудник отдела реабилитации больных с заболеваниями бронхолегочной системы 

107120, Москва, Земляной Вал, 53. Тел.: (916) 974-68-63.

sytchevameister@gmail.comГрушинаТ. И.GrushinaT. I.

д. м. н., руководитель отдела медицинской реабилитации онкологических больных

107120, Москва, Земляной Вал, 53. Тел.: (916) 774-19-39.

tgrushina@gmail.comГБУ "Московский научно-практический центр медицинской реабилитации, восстановительной и спортивной медицины" Департамента здравоохранения МосквыRussian Federation201328122013068591Copyright © Сычева М.Г., Грушина Т.И., 20132013Сычева М.Г., Грушина Т.И.Sycheva M.G., Grushina T.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/313

Медикаментозные средства предотвращения и минимизации лучевых повреждений легких

Drug therapy to prevent and diminish radiation injury of the lungs.

лучевая терапиярадиационно-индуцированные повреждения легкихпневмонитпневмофиброзмедикаментозные средстварадиопротекторымитигаторыradiotherapyradiation induced lung injuryradiation pneumonitisradiation fibrosismedicationsradioprotectorsmitigatorsReferencesGhafoori P., Marks L.B., Vujaskovic Z., Kelsey C.R. Radiation-induced lung injury. Assessment, management and prevention. Oncology 2008; 22 (1): 37–47.Ghafoori P., Marks L.B., Vujaskovic Z., Kelsey C.R. Radiation-induced lung injury. Assessment, management and prevention. Oncology 2008; 22 (1): 37–47.Graves P.R., Siddiqui F., Anscher M.S., Movsas B. Radiation pulmonary toxicity: from mechanisms to management. Semin. Radiat. Oncol. 2010; 20 (3): 201–217.Graves P.R., Siddiqui F., Anscher M.S., Movsas B. Radiation pulmonary toxicity: from mechanisms to management. Semin. Radiat. Oncol. 2010; 20 (3): 201–217.Westbury C.B., Yarnold J.R. Radiation fibrosis – current clinical and therapeutic perspectives. Clin. Oncol. (Roy. Coll. Radiol.) 2012; 24 (10): 657–672.Westbury C.B., Yarnold J.R. Radiation fibrosis – current clinical and therapeutic perspectives. Clin. Oncol. (Roy. Coll. Radiol.) 2012; 24 (10): 657–672.Medhora M., Gao F., Jacobs E. R., Moulder J. E. Radiation damage to the lung: Mitigation by angiotensin-converting enzyme (ACE) inhibitors. Respirology 2012; 17 (1): 66–71.Medhora M., Gao F., Jacobs E. R., Moulder J. E. Radiation damage to the lung: Mitigation by angiotensin-converting enzyme (ACE) inhibitors. Respirology 2012; 17 (1): 66–71.Citrin D., Cotrim A.P., Hyodo F. et al. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010; 15: 360–371.Citrin D., Cotrim A.P., Hyodo F. et al. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010; 15: 360–371.Patel V.N., Gupta S., Shareef M.M., Ahmed M.M. Contemporary radiation countermeasures. Defence Sci. J. 2011; 61 (2): 138–145.Patel V.N., Gupta S., Shareef M.M., Ahmed M.M. Contemporary radiation countermeasures. Defence Sci. J. 2011; 61 (2): 138–145.Movsas B., Vikram B., Hauer-Jensen M. et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators. Clin. Cancer Res. 2011; 17 (2): 222–228.Movsas B., Vikram B., Hauer-Jensen M. et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators. Clin. Cancer Res. 2011; 17 (2): 222–228.Васин М.В. Классификация противолучевых средств как отражение современного состояния и перспективы развития радиационной фармакологии. Радиационная биология. Радиоэкология 2013; 53 (5): 459–467.Васин М.В. Классификация противолучевых средств как отражение современного состояния и перспективы развития радиационной фармакологии. Радиационная биология. Радиоэкология 2013; 53 (5): 459–467.Стюарт Ф.А., Аклеев А.В., Хауэр-Дженсен М. и др. Отчет МКРЗ по тканевым реакциям, ранним и отдаленным эффектам в нормальных тканях и органах – пороговые дозы для тканевых реакций в контексте радиационной защиты (Труды МКРЗ; публикация 118): Пер. с англ. Под ред. А.В.Аклеева, М.Ф.Киселева. Челябинск: Книга 2012.Стюарт Ф.А., Аклеев А.В., Хауэр-Дженсен М. и др. Отчет МКРЗ по тканевым реакциям, ранним и отдаленным эффектам в нормальных тканях и органах – пороговые дозы для тканевых реакций в контексте радиационной защиты (Труды МКРЗ; публикация 118): Пер. с англ. Под ред. А.В.Аклеева, М.Ф.Киселева. Челябинск: Книга 2012.Antonadou D., Coliarakis N., Synodinou M. et al. Randomized phase III trial of radiation treatment / amifostine in patients with advanced-stage lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 915–922.Antonadou D., Coliarakis N., Synodinou M. et al. Randomized phase III trial of radiation treatment / amifostine in patients with advanced-stage lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 915–922.Antonadou D., Petridis A., Synodinou M. et al. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin. Oncol. 2003; 30 (6, Suppl. 18): 2–9.Antonadou D., Petridis A., Synodinou M. et al. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin. Oncol. 2003; 30 (6, Suppl. 18): 2–9.CTEP Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS, March 1998: 24; app IV: 32.CTEP Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS, March 1998: 24; app IV: 32.Komaki R., Lee J.S., Kaplan B. et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II–III non-small cell lung cancer: Preliminary results. Semin. Radiat. Oncol. 2002; 12 (Suppl. 1): 46–49.Komaki R., Lee J.S., Kaplan B. et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II–III non-small cell lung cancer: Preliminary results. Semin. Radiat. Oncol. 2002; 12 (Suppl. 1): 46–49.Marks L.B., Yu X., Vujaskovic Z. Radiation-induced lung injury. Semin. Radiat. Oncol. 2003; 13: 333–345.Marks L.B., Yu X., Vujaskovic Z. Radiation-induced lung injury. Semin. Radiat. Oncol. 2003; 13: 333–345.Tsoutsou P.G., Koukourarakis M.I. Radiation pneumonitis and fibrosis: mechanism underlying its pathogenesis and implications for future researche. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66 (5): 1281–1293.Tsoutsou P.G., Koukourarakis M.I. Radiation pneumonitis and fibrosis: mechanism underlying its pathogenesis and implications for future researche. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66 (5): 1281–1293.Movsas B., Scott C., Langer C. et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98–01. J. Clin. Oncol. 2005; 23: 2145–2154.Movsas B., Scott C., Langer C. et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98–01. J. Clin. Oncol. 2005; 23: 2145–2154.Ozturk B., Egehan I., Atavci S., Kitapci M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58: 213–219.Ozturk B., Egehan I., Atavci S., Kitapci M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58: 213–219.Delanian S., Porcher R., Balla-Mekias S., Lefaix J.-L. Randomized, placebo-controlled trial of combined pentoxifillin and tocopherol for regression of superficial radiationinduced fibrosis. J. Clin. Oncol. 2003; 21 (13): 2545–2550.Delanian S., Porcher R., Balla-Mekias S., Lefaix J.-L. Randomized, placebo-controlled trial of combined pentoxifillin and tocopherol for regression of superficial radiationinduced fibrosis. J. Clin. Oncol. 2003; 21 (13): 2545–2550.Jacobson G., Bhatia S., Smith B.J., Button A.M. Randomized trial of Pentoxifylline and Vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85 (3): 604–608.Jacobson G., Bhatia S., Smith B.J., Button A.M. Randomized trial of Pentoxifylline and Vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85 (3): 604–608.Moulder J.E., Cohen E.P. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin. Radiat. Oncol. 2007; 17: 141–148.Moulder J.E., Cohen E.P. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin. Radiat. Oncol. 2007; 17: 141–148.Molteni A., Moulder J.E., Cohen E.F. et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int. J. Radiat. Biol. 2000; 76 (4): 523–532Molteni A., Moulder J.E., Cohen E.F. et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int. J. Radiat. Biol. 2000; 76 (4): 523–532Molteni A., Wolfe L.F., Ward W.F. et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-β) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Des. 2007; 13: 1307–1316.Molteni A., Wolfe L.F., Ward W.F. et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-β) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Des. 2007; 13: 1307–1316.Ghosh S.N., Zhang R., Fish B.L. et al. Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75 (5): 1528–1536.Ghosh S.N., Zhang R., Fish B.L. et al. Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75 (5): 1528–1536.Medhora M., Gao F., Fish B.L. et al. Dose-modifying factor for captopril for mitigation of radiation injury to normal lung. J. Radiat. Res. 2012; 53 (4): 633–640.Medhora M., Gao F., Fish B.L. et al. Dose-modifying factor for captopril for mitigation of radiation injury to normal lung. J. Radiat. Res. 2012; 53 (4): 633–640.Molthen R.C., Wu Q., Fish B.L. et al. Mitigation of radiation induced pulmonary vascular injury by delayed treatment with captopril. Respirology 2012; 17 (8): 1261–1268. doi: 10.1111/j.1440-1843.2012.02247.x.Molthen R.C., Wu Q., Fish B.L. et al. Mitigation of radiation induced pulmonary vascular injury by delayed treatment with captopril. Respirology 2012; 17 (8): 1261–1268. doi: 10.1111/j.1440-1843.2012.02247.x.Williams J.P., Jackson I.L., Shah J.R. et al. Animal models and medical countermeasures development for radiationinduced lung damage: Report from an NIAID Workshop. Radiat. Res. 2012; 177: e0025–e0039. doi: 10.1667/RROL04.1Williams J.P., Jackson I.L., Shah J.R. et al. Animal models and medical countermeasures development for radiationinduced lung damage: Report from an NIAID Workshop. Radiat. Res. 2012; 177: e0025–e0039. doi: 10.1667/RROL04.1Kharofa J., Cohen E.P., Tomic R. et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2012; 84 (1): 238–243.Kharofa J., Cohen E.P., Tomic R. et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2012; 84 (1): 238–243.Williams J.P, Johnston C.J., Finkelstein J.N. Treatment for radiation-induced pulmonary late effects: Spoiled for choice or looking in the wrong direction? Curr. Drug Targets 2010; 11 (11): 1386–1394.Williams J.P, Johnston C.J., Finkelstein J.N. Treatment for radiation-induced pulmonary late effects: Spoiled for choice or looking in the wrong direction? Curr. Drug Targets 2010; 11 (11): 1386–1394.Sun X.F., Wang L.L., Wang J.K. et al. Effects of simvastatin on lung injury induced by ischaemia-reperfusion of the hind limbs in rats. J. Int. Med Res. 2007; 35: 523–533.Sun X.F., Wang L.L., Wang J.K. et al. Effects of simvastatin on lung injury induced by ischaemia-reperfusion of the hind limbs in rats. J. Int. Med Res. 2007; 35: 523–533.Yao H.W., Mao L.G., Zhu J.P. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin. Exp. Pharmacol. Physiol. 2006; 33: 793–797.Yao H.W., Mao L.G., Zhu J.P. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin. Exp. Pharmacol. Physiol. 2006; 33: 793–797.Xia D.H., Xi L., Xy C. et al. The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. Med. Oncol. 2010; 27 (3): 697–701. doi:10.1007/s12032-009-9271-3.Xia D.H., Xi L., Xy C. et al. The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. Med. Oncol. 2010; 27 (3): 697–701. doi:10.1007/s12032-009-9271-3.Demedts M., Behr J., Buhl R. et al. High-dose Acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229–2242.Demedts M., Behr J., Buhl R. et al. High-dose Acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229–2242.Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377 (9779): 1760–1769.Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377 (9779): 1760–1769.Bargagli E., Galeazzi M., Bellisai F. et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respir. Intern. Rev. Thorac. Dis. 2008; 75 (3): 346–349.Bargagli E., Galeazzi M., Bellisai F. et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respir. Intern. Rev. Thorac. Dis. 2008; 75 (3): 346–349.Staroslawska E., Czarnocki K. J., Koziol-Montewka M. et al. Effect of infliximab on the levels of TNF-α and TGF-β in the whole blood cultures of irradiated patients. Folia Histochem. Cytobiol. 2008; 46 (3): 291–297.Staroslawska E., Czarnocki K. J., Koziol-Montewka M. et al. Effect of infliximab on the levels of TNF-α and TGF-β in the whole blood cultures of irradiated patients. Folia Histochem. Cytobiol. 2008; 46 (3): 291–297.Hunter N.R., Valdecanas D., Liao Z. et al. Mitigation and treatment of radiation-induced thoracic injury with a cyclooxygenase-2 inhibitor, celecoxib. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85 (2): 472–476. doi: 10.1016/j.ijrobp.2012. 04.025.Hunter N.R., Valdecanas D., Liao Z. et al. Mitigation and treatment of radiation-induced thoracic injury with a cyclooxygenase-2 inhibitor, celecoxib. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85 (2): 472–476. doi: 10.1016/j.ijrobp.2012. 04.025.Komaki R., Wei X., Allen P.K. et al. Phase I study of Celecoxib with concurrent Irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front. Oncol. 2011; 1: 52. Published online 2011 December 13.Komaki R., Wei X., Allen P.K. et al. Phase I study of Celecoxib with concurrent Irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front. Oncol. 2011; 1: 52. Published online 2011 December 13.Epperly M., Bray J., Kraeger S. et al. Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther. 1998; 5: 196–208.Epperly M., Bray J., Kraeger S. et al. Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther. 1998; 5: 196–208.Lefaix J.-L., Delanian S., Leplat J.J. et al. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: An experimental study. Int. J. Radiat. Oncol. Biol. Phys. 1996; 35: 305–312.Lefaix J.-L., Delanian S., Leplat J.J. et al. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: An experimental study. Int. J. Radiat. Oncol. Biol. Phys. 1996; 35: 305–312.Kang S.K., Rabbani Z.N., Folz R.J. et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int. J. Radiat. Biol. Oncol. Phys. 2003; 47: 1056–1066.Kang S.K., Rabbani Z.N., Folz R.J. et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int. J. Radiat. Biol. Oncol. Phys. 2003; 47: 1056–1066.Rabbani Z.N., Anscher M.S., Folz R.J. et al. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer 2005; 5: 59. doi:10.1186/1471-2407-5-59.Rabbani Z.N., Anscher M.S., Folz R.J. et al. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer 2005; 5: 59. doi:10.1186/1471-2407-5-59.Vujaskovic Z., Batinic-Haberle I., Rabbani Z.N. et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 2002; 33: 857–863.Vujaskovic Z., Batinic-Haberle I., Rabbani Z.N. et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 2002; 33: 857–863.Mahmood J., Jelveh S., Calveley V. et al. Mitigation of radiation-induced lung injury by genistein and EUK-207. Int. J. Radiat. Biol. 2011; 87 (8): 889–901.Mahmood J., Jelveh S., Calveley V. et al. Mitigation of radiation-induced lung injury by genistein and EUK-207. Int. J. Radiat. Biol. 2011; 87 (8): 889–901.Mahmood J., Jelveh S., Zaidi A. et al. Mitigation of radiation-induced lung injury with EUK-207 and genistein: effects in adolescent rats. Radiat. Res. 2013; 179 (2): 125–134.Mahmood J., Jelveh S., Zaidi A. et al. Mitigation of radiation-induced lung injury with EUK-207 and genistein: effects in adolescent rats. Radiat. Res. 2013; 179 (2): 125–134.Kunwar A., Jain V.K., Priyadarsini K.I., Haston C.K. A Selenocysteine Derivative therapy affects radiation-induced pneumonitis in the mouse. Am. J. Respir. Cell. Mol. Biol. 2013; 49 (4): 654–661.Kunwar A., Jain V.K., Priyadarsini K.I., Haston C.K. A Selenocysteine Derivative therapy affects radiation-induced pneumonitis in the mouse. Am. J. Respir. Cell. Mol. Biol. 2013; 49 (4): 654–661.Драчев И.С., Легеза В.И., Турлаков Ю.С. Перспективы применения соединений селена в качестве радиопротекторов. Радиац. биол. радиоэкол. 2013; 53 (5): 475–480.Драчев И.С., Легеза В.И., Турлаков Ю.С. Перспективы применения соединений селена в качестве радиопротекторов. Радиац. биол. радиоэкол. 2013; 53 (5): 475–480.Yazici G., Yildis F., Iskit A. et al. The effect of vitamin D prophylaxis on radiation induced pulmonary damage. J. Radiat. Res. 2011; 52 (5): 616–621.Yazici G., Yildis F., Iskit A. et al. The effect of vitamin D prophylaxis on radiation induced pulmonary damage. J. Radiat. Res. 2011; 52 (5): 616–621.Lee J.C, Kinniry P.A., Arguiri E. et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat. Res. 2010; 173 (5): 590–601.Lee J.C, Kinniry P.A., Arguiri E. et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat. Res. 2010; 173 (5): 590–601.Cho Y.J., Yi Ch.O., Jeon B.T. et al. Curcumin attenuates radiation-induced inflammation and fibrosis in rat lungs. Korean J. Physiol. Pharmacol. 2013; 17 (4): 267–274. English. Published online 2013 July 30.Cho Y.J., Yi Ch.O., Jeon B.T. et al. Curcumin attenuates radiation-induced inflammation and fibrosis in rat lungs. Korean J. Physiol. Pharmacol. 2013; 17 (4): 267–274. English. Published online 2013 July 30.Liu Y., Yu H., Zhang C. Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur. J. Cancer 2008; 44: 2425–2432.Liu Y., Yu H., Zhang C. Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur. J. Cancer 2008; 44: 2425–2432.Calveley V.L., Jelveh S., Langan A. et al. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat. Res. 2010; 173 (5): 602–611.Calveley V.L., Jelveh S., Langan A. et al. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat. Res. 2010; 173 (5): 602–611.Xavier S., Piek E., Fujii M. et al. Amelioration of radiationinduced fibrosis: inhibition of transforming growth factorbeta signalling by halofuginone. J. Biol. Chem. 2004; 279 (15): 15167–15176.Xavier S., Piek E., Fujii M. et al. Amelioration of radiationinduced fibrosis: inhibition of transforming growth factorbeta signalling by halofuginone. J. Biol. Chem. 2004; 279 (15): 15167–15176.Liu H., Xue J.X., Li X. et al. Quercetin liposomes protect against radiation-induced pulmonary injury in a murine model. Oncol. Lett. 2013; 6 (2): 453–459.Liu H., Xue J.X., Li X. et al. Quercetin liposomes protect against radiation-induced pulmonary injury in a murine model. Oncol. Lett. 2013; 6 (2): 453–459.Robb W.B., Condron C., Moriarty M. et al. Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice. Irish J. Med. Sci. 2010; 179 (1): 99–105.Robb W.B., Condron C., Moriarty M. et al. Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice. Irish J. Med. Sci. 2010; 179 (1): 99–105.Brizel D.M. Pharmacologic approaches to radiation protection. J. Clin. Oncol. 2007; 25 (26): 4084–4089.Brizel D.M. Pharmacologic approaches to radiation protection. J. Clin. Oncol. 2007; 25 (26): 4084–4089.Haiping Z., Takayama K., Uchino J. et al. Prevention of radiation-induced pneumonitis by recombinant adenovirusmediated transferring of soluble TGF-beta type II receptor gene. Cancer Gene Ther. 2006; 13 (9): 864–872.Haiping Z., Takayama K., Uchino J. et al. Prevention of radiation-induced pneumonitis by recombinant adenovirusmediated transferring of soluble TGF-beta type II receptor gene. Cancer Gene Ther. 2006; 13 (9): 864–872.Katoh H., Ishikawa H., Hasegava M. et al. Protective effect of urinary trypsin inhibitor on the development of radiationinduced lung fibrosis in mice. J. Radiat. Res. 2010; 51 (3): 325–332.Katoh H., Ishikawa H., Hasegava M. et al. Protective effect of urinary trypsin inhibitor on the development of radiationinduced lung fibrosis in mice. J. Radiat. Res. 2010; 51 (3): 325–332.Shimbo T., Inomata T., Takahashi M.et al. Effects of sivelestat sodium hydrate on the reduction of radiation pneumonitis. Int. J. Mol. Med. 2007; 20 (6): 817–822.Shimbo T., Inomata T., Takahashi M.et al. Effects of sivelestat sodium hydrate on the reduction of radiation pneumonitis. Int. J. Mol. Med. 2007; 20 (6): 817–822.Fox J., Haston C.K. CXC receptor 1 and 2 and neutrophil elastase inhibitors alter radiation-induced lung disease in the mouse. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85 (1): 215–222. doi: 10.1016/j.ijrobp.2012.02.024.Fox J., Haston C.K. CXC receptor 1 and 2 and neutrophil elastase inhibitors alter radiation-induced lung disease in the mouse. Int. J. Radiat. Oncol. Biol. Phys. 2013; 85 (1): 215–222. doi: 10.1016/j.ijrobp.2012.02.024.Li M., Abdollahi A., Grone H.L. et al. Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat. Oncol. 2009; 4: 66. Published online 2009 December 21.Li M., Abdollahi A., Grone H.L. et al. Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat. Oncol. 2009; 4: 66. Published online 2009 December 21.

The authors declare that there are no conflicts of interest present.